Welcome to the e-CCO Library!

P241: Advantages of a fully automated chemiluminescent method for therapeutic drug monitoring (TDM) of anti-TNFα in patients with Inflammatory Bowel Diseases.
Year: 2022
Source: ECCO'22
Authors: Cifù, A.(1);Marino, M.(2);Sablich, R.(3);Carletti, M.(4);Blasone, N.(4);Milloch, S.(4);Curcio, F.(1);Fabris, M.(4);
Created: Friday, 11 February 2022, 3:52 PM
P241: Defining patient-centered outcomes for IBD – an international, cross-disciplinary consensus
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kim A.*1, Roberts C.2, Feagan B.3, Banerjee R.4, Bemelman W.5, Bodger K.6,7, Derieppe M.8, Dignass A.9, Driscoll R.10, Fitzpatrick R.11, Higgins P.12, Kotze P.13, Meissner J.14, O'Connor M.15, Ran Z.-H.16, Siegel C.17, Terry H.18, van Deen W.19,20, van der Woude C.21, Weaver A.14, Yang S.-K.22, Sands B.23, Vermeire S.24, Travis S.1

Created: Wednesday, 20 February 2019, 10:36 AM
P241: Focussing on the future: reducing barriers and improving access to IBD specialty care
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Heisler*1, O. Kits2, S. Veldhuyzen van Zanten3, J. Jones2

Created: Friday, 22 February 2019, 9:41 AM
P241: Gastrointestinal ultrasonography diagnostic performance and feasibility in IBD during pregnancy: a systematic review and narrative synthesis.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Pillet, J.(1);Perrin, J.(2);Martel, M.(3);Kherad, O.(4);Restellini, S.(5)*;
Created: Friday, 14 July 2023, 10:48 AM
P241: Gastrointestinal ultrasound instead of magnetic resonance enterography: Large potential cost savings with limited clinical downsides
Year: 2021
Source: ECCO'21 Virtual
Authors: LuberMBBS Hons, R.(1);Petri, B.(1);Griffin, N.(2);Irving, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P241: Predictive factors of bone loss in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Hammami*, B. Hasnaoui, M. Ksiaa, H. Jaziri, N. Elleuch, A. Brahem, S. Ajmi, A. Ben Slama, A. Jmaa

Created: Thursday, 21 February 2019, 9:14 AM
P241: Risk factors associated with perianal Crohn’s disease in Korean children
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. Ryoo*, K. Lim, H. Tchah

Created: Friday, 22 February 2019, 9:49 AM
P242 Prior pregnancy outcome is an important determinant of subsequent pregnancy outcome in women with inflammatory bowel diseases
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Rottenstreich1, S. Fridman Lev2, R. Rotem2, T. Mishael2, B. Koslowsky2, E. Goldin2, S. Grisaru-Granovsky2, A. Bar-Gil Shitrit2

Created: Thursday, 30 January 2020, 10:12 AM
P242: Accuracy of Doppler transabdominal ultrasound in assessing disease severity and extent in IBD
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Sagami*1, T. Kobayashi1, T. Kanazawa2, K. Aihara2, H. Morikubo1,3, R. Ozaki1,3, S. Okabayashi1, M. Matsubayashi1,3, A. Fuchigami1,3, H. Kiyohara1,3, M. Nakano1,3, T. Hibi1

Created: Friday, 22 February 2019, 9:41 AM
P242: Latent Tuberculosis: frequency of occurrence and effect on clinical, laboratory, endoscopic and morphological activity of the course Inflammatory Bowel Diseases
Year: 2022
Source: ECCO'22
Authors: Babayeva-Sadigova, G.(1,2);Makhmudov , U.(3);Asadova , G.(1,4);Quliyev , F.(4);Samadova , T.(1,4);Mirzazade, O.(1);Hasanova , A.(1);
Created: Friday, 11 February 2022, 3:52 PM
P242: Newly diagnosed Inflammatory Bowel Disease patients referred via the Straight To Test Lower GI two week wait pathway, Single Centre Study.
Year: 2021
Source: ECCO'21 Virtual
Authors: Samarasinghe, M.(1);Chariah, F.(1);Desilva, C.(1);Koutsoumpas, A.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P242: Performance of the BÜHLMANN Quantum Blue® Infliximab point-of-care assay dedicated for therapeutic drug monitoring of serum infliximab trough levels
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Schuster*, E. Keller, S. Kräuchi, F. Bantleon, J. Weber, M. Schneider

Created: Friday, 22 February 2019, 9:49 AM
P242: Phenotypic characterisation of elderly – onset inflammatory bowel disease – IBD at the extremes
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Nosegbe U.*1, Scott J.A.2, Crooks B.2, Miller B.2, Limdi J.2,3

Created: Wednesday, 20 February 2019, 10:36 AM
P242: The prevalence of sarcopenia and its effect on prognosis in patients with Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

D.J. Oh1, H. Yoon1*, Y.J. Choi1, C.M. Shin1, Y.S. Park1, N. Kim1,2, D.H. Lee1,2

Created: Thursday, 21 February 2019, 9:14 AM
P242: Universal exclusion of patients with Permanent Ileostomy in Crohn's disease clinical trials: A systematic review
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vuyyuru, S.(1);Solitano, V.(1);Nguyen, T.(2);Rieder, F.(3,4);Jairath, V.(1,2,5)*;
Created: Friday, 14 July 2023, 10:48 AM
P243 Changes in the therapeutic management of inflammatory bowel disease in the biological era – a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Zhao1, M. Lördal2, E. Langholz3, T. Knudsen4, M. Voutilainen5, M.L. Høivik6, B. Moum7, B. Saebo8, P. Haiko9, C. Malmgren10, M. Coskun11, H.O. Melberg12, J. Burisch13

Created: Thursday, 30 January 2020, 10:12 AM
P243: Colectomy rates in ulcerative colitis are low and decreasing: Ten-year follow-up data from the Swiss IBD cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Parragi1, N. Fournier2, J. Zeitz3, M. Scharl1, T. Greuter1, P. Schreiner1, B. Misselwitz1, E. Safroneeva4, A. Schoepfer5, S.R. Vavricka6, G. Rogler1, L. Biedermann on behalf of the Swiss IBD Cohort Study Group7*

Created: Thursday, 21 February 2019, 9:14 AM
P243: Complications of newly diagnosed Crohn's disease can be predicted by mathematical modeling of serologic responses
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Yanai H.*1,2, Ben-Shachar S.2,3, Maharshak N.1,2, Ron Y.1,2, Leshno M.2,4, Dotan I.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P243: Developing a protocol to conduct a student-driven study across Europe: EuroSurg-1 study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Pellino on behalf of EuroSurg Collaborative*

Created: Friday, 22 February 2019, 9:49 AM
P243: Elevated presepsin levels are a marker of sepsis risk in patients with inflammatory bowel diseases receiving therapy of TNF-α blockers.
Year: 2021
Source: ECCO'21 Virtual
Authors: Knyazev, O.(1,2,3);Kagramanova, A.(1);Lishchinskaya, A.(1);Li, I.(1);Noskova, K.(4);Fadeeva, N.(5);Subbotin, V.(1);Demchenko, A.(1);Babayan, A.(1);Zvyaglova, M.(1);Kulakov, D.(1,6);
Created: Wednesday, 2 June 2021, 4:12 PM